Business
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ( ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update\nVANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7J0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a corporate update. As Rakovina enters 2026, the Company is advancing its three primary drug discovery programs toward key value-creating milestones. For kt-5000, lead optimization continues with Variational AI, with lead candidate selection and IND-enabling studies targeted for the second half of 2026. For kt-3283, in vivo ADME and efficacy testing of the LNP formulation is underway with NanoPalm. For kt-2000, a second round of AI output and in vitro testing is advancing. Across all programs, the Company intends to progress pharmaceutical partnership discussions as preclinical data matures. “Completing the first phase of our restructuring marks an important inflection point for Rakovina,” said Kim Oishi, CEO of Rakovina. “Through the recent debenture restructuring, new financing, and the strengthening of our board and executive team, we are well on our way to repositioning the Company for success. As we continue to put our financial house in order, we are sharpening our focus on execution — advancing our DDR inhibitor pipeline, expanding our strategic partnerships, and unlocking the full potential of our world-class AI-driven drug discovery engine to deliver value for our shareholders.” 2025 Highlights and Recent Developments Leadership and Board On January 27, 2026, Rakovina appointed Kim Oishi as Chief Executive Officer. Mr. Oishi brings over 25 years of capital markets experience, including as founder of Grand Rock Capital Inc. and partner at First Growth Equity Partners Inc.On January 27, 2026, Rakovina welcomed Frank Holler to its Board of Directors. Mr. Holler has been directly involved in the founding and development of a number of Canada’s leading biopharma companies, including ID Biomedical Corp., Angiotech Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc.On May 5, 2025, Ra...